Tanezumab

Drug Profile

Tanezumab

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 14 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rinat Neuroscience
  • Developer Eli Lilly; Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain; Pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 13 Jun 2017 Tanezumab receives Fast Track designation for Back pain [SC,IV] in USA
  • 13 Jun 2017 Tanezumab receives Fast Track designation for Musculoskeletal pain (due to osteoarthritis) [SC,IV] in USA
  • 23 Jan 2017 Pfizer and Eli Lilly plan a follow-up, observational phase III trial for Cancer pain, Back pain and Musculoskeletal pain (In neonates, In infants, In children) (NCT03031938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top